KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Expenses: 2009-2024

Historic Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $2.4 billion.

  • Alnylam Pharmaceuticals' Operating Expenses rose 52.48% to $881.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 29.02%. This contributed to the annual value of $2.4 billion for FY2024, which is 14.91% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Operating Expenses stood at $2.4 billion for FY2024, which was up 14.91% from $2.1 billion recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Operating Expenses ranged from a high of $2.4 billion in FY2024 and a low of $1.3 billion during FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Operating Expenses value was $2.1 billion (recorded in 2023), while the average stood at $2.1 billion.
  • Data for Alnylam Pharmaceuticals' Operating Expenses shows a peak YoY rose of 17.53% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Operating Expenses stood at $1.3 billion in 2020, then rose by 17.53% to $1.6 billion in 2021, then rose by 17.36% to $1.8 billion in 2022, then increased by 15.80% to $2.1 billion in 2023, then increased by 14.91% to $2.4 billion in 2024.